Immunohistochemical expression of oestrogen receptor‐α and progesterone receptor in salivary gland tumours

Kolude, Bamidele; Adisa, Akinyele Olumuyiwa; Adeyemi, B F; Lawal, A O

doi:10.1111/jop.12071

Cited by 8 publications

(12 citation statements)

References 25 publications

(51 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The overexpression of PR and ER described in the literature is consistent with the findings of our study, where only 2.5% of cases were ER and PR positive. 18,22,23 However, some authors, such as Kolude et al, 24 have reported higher rates. Those authors found that 28% and 8%, respectively, of tumors were ER+ and PR+, although these findings were not statistically significant.…”

Section: Overexpression Of Pr and Ermentioning

confidence: 98%

Prognostic markers in salivary gland cancer and their impact on survival

et al. 2019

View full text Add to dashboard Cite

Background The role of molecular markers in salivary gland carcinoma (SGC) is not well understood. We evaluated molecular marker expression and their prognostic value. Methods Immunohistochemical analysis of 124 tumor specimens was performed to determine expression of androgen (AR), estrogen (ER), and progesterone (PR) receptors and epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), programmed death ligand 1 receptor (PD‐L1), and PD‐L1 in tumor‐infiltrating mononuclear cell (TIMC). Survival outcomes (disease‐free survival [DFS] and overall survival [OS]), pT and N classification, margin status, and treatment failure were assessed. Results Most patients (78; 62.9%) had early‐stage SGC. AR positivity and EGFR positivity were detected in 21.0% and 78.6%, respectively, of tumors. AR positivity and PD‐L1 negativity were associated with locally advanced disease. PD‐L1‐negativity was associated with higher recurrence (38.5% vs 0%; P < .001) and worse DFS. OS and DFS were worse in patients with AR+ or HER2+ disease. Conclusions Several molecular markers—AR and HER2 positivity and PD‐L1 negativity—were associated with worse clinical outcomes. Prospective, multi‐institutional trials are needed to determine the prognostic value of these markers.

show abstract

Section: Overexpression Of Pr and Ermentioning

confidence: 98%

Prognostic markers in salivary gland cancer and their impact on survival

et al. 2019

View full text Add to dashboard Cite

show abstract

“…If estrogen indeed has an effect on both risk of SGC and risk of SGPA, this could also explain the reported female preponderance of SGC and SGPA. In the literature, generally only a small portion of salivary gland tumors show ER‐overexpression based on immunohistochemistry, possibly because mainly ER‐α and not ER‐β expression status has been assessed 45–51 . Nevertheless, although ER‐β expression in salivary gland tumors was only reported in a limited number of series, ER‐β was overexpressed in 27 of 38 (71%) patients in a series of adenoid cystic carcinomas and in 57 of 80 (73%) in a series of salivary duct carcinomas 16,52 …”

Section: Discussionmentioning

confidence: 99%

Risk of breast cancer in women after a salivary gland carcinoma or pleomorphic adenoma in the Netherlands

Valstar

Schaapveld

Broek³

et al. 2020

Cancer Medicine

View full text Add to dashboard Cite

Salivary and mammary gland tumors show morphological similarities and share various characteristics, including frequent overexpression of hormone receptors and female preponderance. Although this may suggest a common etiology, it remains unclear whether patients with a salivary gland tumor carry an increased risk of breast cancer (BC). Our purpose was to determine the risk of BC in women diagnosed with salivary gland carcinoma (SGC) or pleomorphic adenoma (SGPA). BC incidence (invasive and in situ) was assessed in two nationwide cohorts: one comprising 1567 women diagnosed with SGC and one with 2083 women with SGPA. BC incidence was compared with general population rates using standardized incidence ratio (SIR). BC risk was assessed according to age at SGC/SGPA diagnosis, follow‐up time and (for SGC patients) histological subtype. The mean follow‐up was 7.0 years after SGC and 9.9 after SGPA diagnosis. During follow‐up, 52 patients with SGC and 74 patients with SGPA developed BC. The median time to BC was 6 years after SGC and 7 after SGPA. The cumulative risk at 10 years of follow‐up was 3.1% after SGC and 3.5% after SGPA (95% Confidence Interval (95%CI) 2.1%–4.7% and 2.6%–4.6%, respectively). BC incidence was 1.59 times (95%CI 1.19–2.09) higher in the SGC‐cohort than expected based on incidence rates in the general population. SGPA‐patients showed a 1.48 times (95%CI 1.16–1.86) higher incidence. Women with SGC or SGPA have a slightly increased risk of BC. The magnitude of risk justifies raising awareness, but is no reason for BC screening.

show abstract

“…In the literature, in most of the studies, neither an ER nor a PR expression has been detected in a variety of benign tumors, such as PA, Warthin tumor, oncocytoma, basal cell adenoma, and myoepithelioma, demonstrating that these factors have no influence in the development tumors of the salivary glands. 26,30,31,43,44 Although some authors have considered that the ERβ expression may have contributed to the development of PA, this antibody was not researched in this study. 45…”

Section: Discussionmentioning

confidence: 99%

“…22 The involvement of ER, PR, and HER-2 is also described in benign and malignant salivary gland tumors. 15,23-34 A few studies on hormone and HER-2 therapy to treat malignant tumors of the salivary gland have been published. 35-38…”

Section: Introductionmentioning

confidence: 99%

Estrogen Receptor, Progesterone Receptor, and HER-2 Expression in Recurrent Pleomorphic Adenoma

Souza

Altemani

Araújo

et al. 2019

Clin Med�Insights�Pathol

View full text Add to dashboard Cite

Pleomorphic adenoma (PA) is the most common salivary gland neoplasm and, although mostly benign, recurrences, being called recurrent pleomorphic adenoma (RPA) and malignant transformation to carcinoma ex pleomorphic adenoma (CXPA), do occur. Recently, attention has been focused on molecular targeted cancer therapy in various tumors, including salivary gland tumors. The aim of this study was to investigate the role of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor-2 (HER-2) in PA, RPA, and CXPA. In total, 20 cases of PA, 18 of RPA, and 7 cases of CXPA were immunohistochemically studied for ER, PR, and HER-2. For evaluation of ER and PR, only nuclear expression and greater than 10% positive cells were regarded as cutoff criteria. HER-2 was evaluated semiquantitatively and graded from 0 to 3+. HER-2 amplification was assessed by chromogenic in situ hybridization (CISH). Tumors were negative for ER, PR, and HER-2 in all cases of PA and RPA. A case of CXPA showed moderate and complete membranous staining, and 6 cases were negative. HER-2 amplification was not observed in any case. In conclusion, the lack of ER, PR, and HER-2 expression in PA, RPA, and CXPA suggests that these proteins are not involved in progression, recurrence, or malignant transformation of PA.

show abstract

Immunohistochemical expression of oestrogen receptor‐α and progesterone receptor in salivary gland tumours

Abstract: This study showed that ER-α was expressed more in the high-grade malignant SGTs compared with the low-grade malignant SGTs and the benign SGTs.

Cited by 8 publications

References 25 publications

Prognostic markers in salivary gland cancer and their impact on survival

Prognostic markers in salivary gland cancer and their impact on survival

Risk of breast cancer in women after a salivary gland carcinoma or pleomorphic adenoma in the Netherlands

Estrogen Receptor, Progesterone Receptor, and HER-2 Expression in Recurrent Pleomorphic Adenoma

Contact Info

Product

Resources

About